

RECEIVED  
CENTRAL FAX CENTER10333 Richmond, Suite 1100  
Houston, TX 77042  
Phone: 713-934-7000  
Fax: 713-934-7011

JUL 05 2005

**Williams, Morgan &  
Amerson, P.C.****Fax**

<b>To:</b>	Examiner Chih-Min Kam Group Art Unit 1853	<b>From:</b>	Kenneth D. Goodman Reg. No. 30,460
<b>Fax:</b>	1-703-872-9308	<b>Phone:</b>	713-934-4094
<b>No. of Pages:</b>	5	<b>Date:</b>	July 5, 2005
<b>Re:</b>	Serial No. 10/027,015	<b>File:</b>	2103.000500

\*w/ coversheet

ORIGINAL: Will follow XX Will not follow

•Comments:

## CONFIDENTIALITY NOTE

The documents accompanying this facsimile transmission contain information from the law firm of Williams, Morgan & Amerson which may be confidential and/or privileged. The information is intended to be for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this faxed information is prohibited. If you have received this facsimile in error, please notify us by telephone immediately so that we can arrange for the retrieval of the original documents at no cost to you.

RECEIVED  
CENTRAL FAX CENTER

NO. 398

082

JUL 05 2005

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

RAMA AKELLA  
JOHN P. RANTERI

Serial No.: 10/027,015

Filed: December 21, 2001

For: COMPOSITIONS AND METHODS FOR  
PROMOTING MYOCARDIAL AND  
PERIPHERAL ANGIOGENESIS

Confirmation No.: 1147

Group Art Unit: 1653

Examiner: Chih-Min Kam

Attorney Docket: 2103,000500/KDG  
(SBI-091)

CUSTOMER NO. 45488

RESPONSE TO RESTRICTION REQUIREMENT  
DATED MAY 5, 2005MAIL STOP AMENDMENT  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450CERTIFICATE OF FACSIMILE  
37 C.F.R. § 1.6(d)I hereby certify that this paper is being facsimile transmitted  
to MAIL STOP AMENDMENT, Commissioner for Patents,  
P. O. Box 1450, Alexandria, VA 22313-1450, facsimile  
number 1-703-872-9306, on this 5<sup>th</sup> day of July 2005.  
Cynde Meinert

Sir:

This paper is submitted in response to the Restriction Requirement dated May 5, 2005, for which the date for response was June 5, 2005. Applicants have filed concurrently with this response a petition for a one-month extension of time pursuant to 37 C.F.R. § 1.136, making the due date for this response July 5, 2005. If the petition is missing, please treat this paper as a petition under § 1.136 for the necessary extension of time.

No fee should be due for this response. If any fees under 37 C.F.R. §§ 1.16 to 1.21 are required for any reason relating to this response, the Director is authorized to deduct the fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/2103.000500KDG.

In the office action, the Examiner issued a restriction requirement. Applicants elect Group I (claims 1-7) without traverse.

The Examiner also required selection of species of peptide and angiogenic growth factor. Applicants select SEQ ID NO. 4 and bone-derived angiogenic proteins (BDAPs).

Please contact the undersigned attorney at (713) 934-4094 if there are any questions regarding this response.

Respectfully submitted,

WILLIAMS, MORGAN & AMERSON, P.C.  
CUSTOMER NO. 45488

July 5, 2005



Kenneth D. Goodman  
Reg. No. 30,460  
10333 Richmond, Suite 1100  
Houston, Texas 77042  
(713) 934-4094  
(713) 934-7011 (fax)

ATTORNEY FOR APPLICANTS